Inventory

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventory

Inventory

Inventory consists of the following:

(in thousands)	SEPTEMBER 30, 2018
Raw materials	$	559
Work-in-process	2,478
Finished goods	2,575
Total inventory	$	5,612

The Company commenced capitalizing inventory for Rhopressa^® upon FDA approval of Rhopressa^® on December 18, 2017. No inventory was produced from the FDA approval date through the end of 2017; therefore, no inventory was capitalized on the consolidated balance sheet as of December 31, 2017.